How to manage the obese patient with cancer

Journal of Clinical Oncology

Volumn 34, Issue 35, 2016, Pages 4284-4294

  Renehan, Andrew G ^a   Harvie, Michelle ^b   Cutress, Ramsey I ^c,d   Leitzmann, Michael ^e   Pischon, Tobias ^f   Howell, Sacha ^a   Howell, Anthony ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; ANTINEOPLASTIC AGENT;

BODY MASS; CANCER CHEMOTHERAPY; CANCER PATIENT; HUMAN; NEOPLASM; OBESITY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; SURGICAL MORTALITY; COMPLICATION; METABOLISM; NEOPLASMS; RISK FACTOR;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; OBESITY; RISK FACTORS;

EID: 85002523731     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.1899     Document Type: Review

References (86)

1. Renehan AG, Zwahlen M, Egger M: Adiposity and cancer risk: New mechanistic insights from epidemiology. Nat Rev Cancer 15:484-498, 2015
2. Lauby-Secretan B, Scoccianti C, Loomis D, et al: Body fatness and cancer-Viewpoint of the IARC Working Group. N Engl J Med 375:794-798, 2016
3. Renehan AG, Tyson M, Egger M, et al: Bodymass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578, 2008
4. Ligibel JA, Wollins D: The American Society of Clinical Oncology Obesity Initiative: Rationale, progress, and future directions. Journal of Clinical Oncology Obesity and Cancer Special Issue. In press
5. Mullen JT, Davenport DL, Hutter MM, et al: Impact of body mass index on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery. Ann Surg Oncol 15:2164-2172, 2008
6. Filardo G, Hamilton C, Hamman B, et al: Categorizing BMI may lead to biased results in studies investigating in-hospital mortality after isolated CABG. J Clin Epidemiol 60:1132-1139, 2007
7. Lennon H, Sperrin M, Badrick E, et al: The obesity paradox in cancer: A review. Curr Oncol Rep 18:56, 2016
8. Song M, Giovannucci E: Estimating the influence of obesity on cancer risk: Stratification by smoking is critical. J Clin Oncol 34:3237-3239, 2016
9. Brewster AM, Etzel C, Zhou R, et al: The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers. Breast Cancer Res Treat 130:897-904, 2011
10. Bokey L, Chapuis PH, Dent OF: Impact of obesity on complications after resection for rectal cancer. Colorectal Dis 16:896-906, 2014
11. Brennan ME, Spillane AJ: Uptake and predictors of post-mastectomy reconstruction in women with breast malignancy-Systematic review. Eur J Surg Oncol 39:527-541, 2013
12. Van De Poll-Franse LV, Houterman S, Janssen-Heijnen ML, et al: Less aggressive treatment and worse overall survival in cancer patients with diabetes: A large population based analysis. Int J Cancer 120:1986-1992, 2007
13. Colleoni M, Li S, Gelber RD, et al: Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 366:1108-1110, 2005
14. Gennari A, Amadori D, Scarpi E, et al: Impact of body mass index (BMI) on the prognosis of highrisk early breast cancer (EBC) patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 159:79-86, 2016
15. Griggs JJ, Sorbero ME, Lyman GH: Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165:1267-1273, 2005
16. Chambers P, Daniels SH, Thompson LC, et al: Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol 23:748-753, 2012
17. Dignam JJ, Polite BN, Yothers G, et al: Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 98:1647-1654, 2006
18. Au-Yeung G, Webb PM, DeFazio A, et al: Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol 133:16-22, 2014
19. Wright JD, Tian C, Mutch DG, et al: Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 109:353-358, 2008
20. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 332:901-906, 1995
21. Wildiers H, Reiser M: Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 77:221-240, 2011
22. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205-1211, 1998
23. Gamelin E, Delva R, Jacob J, et al: Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099-2105, 2008
24. Arriagada R, Le Chevalier T, Pignon JP, et al: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329:1848-1852, 1993
25. Hunter RJ, Navo MA, Thaker PH, et al: Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA). Cancer Treat Rev 35:69-78, 2009
26. Hourdequin KC, Schpero WL, McKenna DR, et al: Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: A systematic review and meta-analysis. Ann Oncol 24:2952-2962, 2013
27. Furlanetto J, Eiermann W, Marmé F, et al: Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: Results of the prospectively randomized GAIN study. Ann Oncol mdw315, 2016
28. Sparreboom A, Wolff AC, Mathijssen RH, et al: Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707-4713, 2007
29. Guenancia C, Lefebvre A, Cardinale, et al: Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: A systematic review and meta-analysis. J Clin Oncol 34:3157-3165, 2016
30. Quartino AL, Hillenbach C, Li J, et al: Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer. Cancer Chemother Pharmacol 77:77-88, 2016
31. Abraham JE, Hiller L, Dorling L, et al: A nested cohort study of 6, 248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapyrelated toxicities. BMC Med 13:306, 2015
32. Wong AL, Seng KY, Ong EM, et al: Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat 144:143-152, 2014
33. Althumairi AA, Canner JK, Gearhart SL, et al: Risk factors for wound complications after abdominoperineal excision: Analysis of the ACS NSQIP database. Colorectal Dis 18:O260-O266, 2016
34. Fischer JP, Nelson JA, Kovach SJ, et al: Impact of obesity on outcomes in breast reconstruction: Analysis of 15, 937 patients from the ACS-NSQIP datasets. J Am Coll Surg 217:656-664, 2013
35. Gedaly R, McHugh PP, Johnston TD, et al: Obesity, diabetes, and smoking are important determinants of resource utilization in liver resection: A multicenter analysis of 1029 patients. Ann Surg 249:414-419, 2009
36. Melis M, Weber J, Shridhar R, et al: Body mass index and perioperative complications after oesophagectomy for adenocarcinoma: A systematic database review. BMJ Open 3:e001336, 2013
37. STARSurg Collaborative: Multicentre prospective cohort study of body mass index and postoperative complications following gastrointestinal surgery. Br J Surg 103:1157-1172, 2016
38. Dindo D, Muller MK, Weber M, et al: Obesity in general elective surgery. Lancet 361:2032-2035, 2003
39. Mustain WC, Davenport DL, Hourigan JS, et al: Obesity and laparoscopic colectomy: Outcomes from the ACS-NSQIP database. Dis Colon Rectum 55:429-435, 2012
40. Robertson SA, Rusby JE, Cutress RI: Determinants of optimal mastectomy skin flap thickness. Br J Surg 101:899-911, 2014
41. Senagore A, Delaney C, Fazio V, et al: Cleveland Clinic Colorectal Laparoscopic Conversion Model. http://www.riskprediction.org.uk/index-ccflap. php
42. Aquina CT, Rickles AS, Probst CP, et al: Visceral obesity, not elevated BMI, is strongly associated with incisional hernia after colorectal surgery. Dis Colon Rectum 58:220-227, 2015
43. Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 27:4027-4034, 2009
44. Goodwin PJ: Obesity and endocrine therapy: Host factors and breast cancer outcome. Breast 22(Suppl 2):S44-S47, 2013
45. Jiralerspong S, Goodwin PJ: Obesity and breast cancer prognosis-Evidence, challenges, and opportunities. Journal of Clinical Oncology Obesity and Cancer Special Issue. doi: 10.1200/JCO.2016.68. 4480
46. Renehan AG: Body fatness and bevacizumabbased therapy in metastatic colorectal cancer. Gut 59:289-290, 2010
47. Guiu B, Petit JM, Bonnetain F, et al: Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 59:341-347, 2010
48. Simkens LH, Koopman M, Mol L, et al: Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur J Cancer 47:2560-2567, 2011
49. Ladoire S, Bonnetain F, Gauthier M, et al: Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist 16:71-81, 2011
50. Steffens S, Grünwald V, Ringe KI, et al: Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist 16:1565-1571, 2011
51. Slaughter KN, Thai T, Penaroza S, et al: Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol 133:11-15, 2014
52. Makari-Judson G, Judson CH, Mertens WC: Longitudinal patterns of weight gain after breast cancer diagnosis: Observations beyond the first year. Breast J 13:258-265, 2007
53. Lankester KJ, Phillips JE, Lawton PA: Weight gain during adjuvant and neoadjuvant chemotherapy for breast cancer: An audit of 100 women receiving FEC or CMF chemotherapy. Clin Oncol (R Coll Radiol) 14:64-67, 2002
54. Gu K, Chen X, Zheng Y, et al: Weight change patterns among breast cancer survivors: Results from the Shanghai breast cancer survival study. Cancer Causes Control 21:621-629, 2010
55. Chaudhary LN, Wen S, Xiao J, et al: Weight change associated with third-generation adjuvant chemotherapy in breast cancer patients. J Community Support Oncol 12:355-360, 2014
56. Han HS, Lee KW, Kim JH, et al: Weight changes after adjuvant treatment in Korean women with early breast cancer. Breast Cancer Res Treat 114:147-153, 2009
57. Reddy SM, Sadim M, Li J, et al: Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. Br J Cancer 109:872-881, 2013
58. Freedman RJ, Aziz N, Albanes D, et al: Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J Clin Endocrinol Metab 89:2248-2253, 2004
59. Makari-Judson G, Braun B, Jerry DJ, et al: Weight gain following breast cancer diagnosis: Implication and proposed mechanisms. World J Clin Oncol 5:272-282, 2014
60. Sedjo RL, Byers T, Ganz PA, et al: Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors. J Cancer Surviv 8:410-418, 2014
61. Goodwin PJ, Ennis M, Pritchard KI, et al: Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17:120-129, 1999
62. Liu LN, Wen FH, Miaskowski C, et al: Weight change trajectory in women with breast cancer receiving chemotherapy and the effect of different regimens. J Clin Nurs 23:2757-2768, 2014
63. Irwin ML, McTiernan A, Baumgartner RN, et al: Changes in body fat and weight after a breast cancer diagnosis: Influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23:774-782, 2005
64. Harvie MN, Campbell IT, Baildam A, et al: Energy balance in early breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 83:201-210, 2004
65. Vagenas D, DiSipio T, Battistutta D, et al: Weight and weight change following breast cancer: Evidence from a prospective, population-based, breast cancer cohort study. BMC Cancer 15:28, 2015
66. Playdon MC, Bracken MB, Sanft TB, et al: Weight gain after breast cancer diagnosis and allcause mortality: Systematic review and meta-analysis. J Natl Cancer Inst 107:djv275, 2015
67. Bradshaw PT, Ibrahim JG, Stevens J, et al: Postdiagnosis change in bodyweight and survival after breast cancer diagnosis. Epidemiology 23:320-327, 2012
68. Nichols HB, Trentham-Dietz A, Egan KM, et al: Body mass index before and after breast cancer diagnosis: Associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 18:1403-1409, 2009
69. Nechuta S, Chen WY, Cai H, et al: A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer 138:2088-2097, 2016
70. Chlebowski RT, Reeves MM: Weight loss randomized intervention trials in women cancer survivors. Journal of Clinical Oncology Special Issue: Obesity and Cancer. In press
71. Ligibel JA, Alfano CM, Courneya KS, et al: American Society of Clinical Oncology position statement on obesity and cancer. J Clin Oncol 32:3568-3574, 2014
72. Chan DS, Vieira AR, Aune D, et al: Bodymass index and survival in women with breast cancer-Systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901-1914, 2014
73. Kwan ML, Chen WY, Kroenke CH, et al: Prediagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 132:729-739, 2012
74. Campbell PT, Newton CC, Dehal AN, et al: Impact of body mass index on survival after colorectal cancer diagnosis: The Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 30:42-52, 2012
75. Ward KK, Shah NR, Saenz CC, et al: Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol 126:176-179, 2012
76. Crosbie EJ, Roberts C, Qian W, et al: Body mass index does not influence post-treatment survival in early stage endometrial cancer: Results from the MRC ASTEC trial. Eur J Cancer 48:853-864, 2012
77. Blanchard CM, Stein K, Courneya KS: Body mass index, physical activity, and health-related quality of life in cancer survivors. Med Sci Sports Exerc 42:665-671, 2010
78. Connor AE, Baumgartner RN, Pinkston CM, et al: Obesity, ethnicity, and quality of life among breast cancer survivors and women without breast cancer: The long-term quality of life follow-up study. Cancer Causes Control 27:115-124, 2016
79. Paxton RJ, Phillips KL, Jones LA, et al: Associations among physical activity, body mass index, and health-related quality of life by race/ethnicity in a diverse sample of breast cancer survivors. Cancer 118:4024-4031, 2012
80. Jansen L, Koch L, Brenner H, et al: Quality of life among long-term ($5 years) colorectal cancer survivors-Systematic review. Eur J Cancer 46:2879-2888, 2010
81. Allott EH, Masko EM, Freedland SJ: Obesity and prostate cancer: Weighing the evidence. Eur Urol 63:800-809, 2013
82. Smits A, Lopes A, Bekkers R, et al: Body mass index and the quality of life of endometrial cancer survivors-A systematic review and meta-analysis. Gynecol Oncol 137:180-187, 2015
83. Smits A, Lopes A, Das N, et al: Quality of life in ovarian cancer survivors: The influence of obesity. Int J Gynecol Cancer 25:616-621, 2015
84. Griggs JJ, Mangu PB, Anderson H, et al: Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 30:1553-1561, 2012
85. Coe PO, O'Reilly DA, Renehan AG: Excess adiposity and gastrointestinal cancer. Br J Surg 101:1518-1531, discussion 1531, 2014
86. James FR, Wootton S, Jackson A, et al: Obesity in breast cancer-What is the risk factor? Eur J Cancer 51:705-720, 2015